Triple-Negative Breast Cancer First In England As NICE Reverses Tecentriq Rejection
Roche has resolved the issues raised by the health technology assessment body over what is the first immunotherapy approved for treating this aggressive and difficult-to-treat form of breast cancer.
You may also be interested in...
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.
NICE draft guidance says that Tecentriq in combination with chemotherapy is not cost effective in untreated advanced triple-negative breast cancer.